FutureChem Co

FutureChem Co P/B

The P/B (Price-to-Book Ratio) of FutureChem Co (220100.KQ) as of Oct 21, 2026 is 8.86. In the previous year, P/B (Price-to-Book Ratio) was 8.91 — a change of -0.50% (lower).

P/B

8.86

YoY

-0.50%

Last updated:

P/B (Price-to-Book Ratio) of FutureChem Co is 2025 8.86 . P/B (Price-to-Book Ratio) of FutureChem Co was 2024 8.91 . It decreases by -0.50% lower compared to the previous year.

The FutureChem Co P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
29.43 KRW
Jan 1, 2019
43.38 KRW
Jan 1, 2020
11.17 KRW
Jan 1, 2021
9.19 KRW
Jan 1, 2022
6.91 KRW
Jan 1, 2023
7.59 KRW
Jan 1, 2024
8.91 KRW
Jan 1, 2025
8.86 KRW
The FutureChem Co P/B history
YEARP/BYoY
8.86-0.50%
8.91+17.27%
7.59+9.98%
6.91-24.84%
9.19-17.72%
11.17-74.26%
43.38+47.40%
29.43+65.30%
17.81+15.93%
15.36-112.03%
-127.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

FutureChem Co Stock analysis

What does FutureChem Co do? FutureChem Co., Ltd. generates revenue through the manufacture and distribution of radiopharmaceuticals, including diagnostic agents for lung cancer, Parkinson's disease, and Alzheimer's disease. The company produces medical automation modules such as cubes, disposable cassettes, reagent kits, radio-caps, and kryptofix kits, alongside PET and SPECT precursors for radiopharmaceuticals. These products are sold to healthcare providers, diagnostic centers, and medical facilities requiring specialized radiopharmaceutical solutions. The firm also develops metal chelating agents and fluorescence probes for medical applications. The primary buyers of FutureChem's products include hospitals, clinics, and research institutions focused on cancer diagnostics and neurological conditions. Medical automation modules and disposable goods are utilized in diagnostic procedures, while PET and SPECT precursors support imaging technologies. Metal chelating agents and fluorescence probes are integrated into medical testing and imaging processes. FutureChem's revenue streams are driven by the demand for advanced diagnostic tools in oncology and neurology. The company's portfolio targets healthcare segments requiring early detection of diseases, with products designed for both diagnostic imaging and laboratory testing. Sales are concentrated in medical facilities that prioritize precision diagnostics and specialized treatment planning. FutureChem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FutureChem Co stock

P/B (Price-to-Book Ratio) of FutureChem Co is 8.86 in 2025.

P/B (Price-to-Book Ratio) of FutureChem Co changed from 8.91 to 8.86, representing a -0.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) FutureChem Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s FutureChem Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — FutureChem Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — FutureChem Co